Who We Are
CellAegis Devices Inc (CDI) is a Toronto-based designer and manufacturer of safe, non-invasive and cost effective, cardio protective medical devices. CellAegis is building on market acceptance of remote ischemic conditioning through continued support of clinical research projects and development of the market world-wide.
CellAegis Devices has developed and commercialized the non-invasive system, the autoRIC® System, which automates delivery of Remote Ischemic Conditioning (RIC) therapy. The autoRIC® is adjunct to standard of care, has the CE Mark and Health Canada Approval. CellAegis Devices is currently commercializing in Europe and Canada, and conducting registration trials in the USA.
Mr. Ganske joined CellAegis in December 2010 as the CEO after having participated on the CellAegis Board of Directors for a year. Mr. Ganske has over 30 years of both public and private company experience in the medical devices, diagnostics and life science fields, and has a broad background in management, operations, science and regulatory; blended with the disciplines of corporate processes, and successful entrepreneurial business ventures. Mr. Ganske has personally led multiple business and IP transactions with both Fortune 100 and Fortune 500 companies.
Prior to CDI, Mr. Ganske served as CEO of Axela, a university diagnostics startup focused on proteomic analysis. Mr. Ganske transitioned Axela to a full operating company, installing Axela’s platform technology in premier institutes in the US, EU and Asia Pacific. Mr. Ganske was instrumental in negotiating and closing significant patent in-licensing transaction with Fortune 100 companies for over 150 patents and applications and oversaw Axela’s acquisition of Xceed Molecular, a genomics diagnostic company.
Mr. Ganske held the position of Chief Operating Officer at Third Wave Technologies (TWTI) in Madison, WI. During his eight year tenure at TWTI, Mr. Ganske was imperative in setting the operational vision and tactical implementation that grew TWTI from a company with great technology to a fully operational company with over $40M of revenue. Third Wave debuted on Nasdaq in February 2001 in an $83 Million IPO, and was bought by Hologic for over $300M.
Prior to Third Wave, Mr. Ganske held various operational, engineering and regulatory management positions over 18 years, including Director of Regulatory Affairs, with Becton Dickinson and Company (BDX).
Mr. Fielding brings over 30 years of strategic, financial, operations and administrative management to CellAegis. Throughout his career Mr. Fielding has worked extensively with Private Equity, Venture and Publicly financed organizations.
Prior to joining CellAegis, Mr. Fielding served as CFO of Therapure BioPharma Inc., creating Canada’s leading provider of biological contract manufacturing services to the Life Science industry as well as a leading drug development company focusing on plasma derived therapeutics, liver cancer, anemia and hepatitis C.
Prior to Therapure BioPharma Inc. Mr. Fielding worked with a broad portfolio of development, service provider and commercial Life Science organizations and has operated as CEO, COO and CFO within these organizations. Mr. Fielding has worked with Medical Device, Diagnostic and Therapeutic technologies throughout his career.
Mr. Fielding is a CA, CPA and has a Bachelor of Commerce from the University of Toronto.
VP, Sales and Marketing Europe
Mr. Custers has over 30 years of sales, marketing, distribution and product development experience in the healthcare industry.
He is currently leading our European Commercialization efforts as VP, Sales and Marketing Europe. Prior to joining CellAegis Devices, Mr. Custers worked with several Medical device and start-up companies including Terumo Europe, CD4MD, and CryoCath/Medtronic.
VP, Clinical and Corporate Development
Ms. Belaoussoff has over 20 years of experience in research and the healthcare industry. She is currently VP, Corporate Development at CellAegis Devices. Prior to joining CellAegis Devices, Ms. Belaoussoff was responsible for pipeline development at YM BioSciences, a development-stage oncology company, where she was responsible for the acquisition of Australian Cytopia Ltd for the JAK inhibitor CYT387, which subsequently resulted in YM BioSciences’ acquisition by US-based Gilead Sciences in 2013.
Ms. Belaoussoff has also provided consulting services to the biotechnology industry, with a focus on strategic development and out-licensing. Ms. Belaoussoff was a healthcare analyst for eight years in the financial services industry, most recently on the buy-side with Scotia Cassels Investment Management where she covered the North American healthcare industry. Prior to that, she was a healthcare analyst in the brokerage industry and participated in over $80 million of biotech financing. Ms. Belaoussoff has her M.Sc. (Molecular Biology) from York University in Toronto, and an Honour’s B.Sc. (Genetics) from the University of Manitoba.
Quality & Regulatory Affairs Manager
Ms. Shaw brings over 10 years experience within the medical device industry where she has focused on leading innovative, start-up medical device firms through the maze of the quality assurance and regulatory requirements to become successful and viable commercial enterprises.
Ms. Shaw has expertise helping companies certify their Quality Management Systems to ISO 13485 and obtain Health Canada, European (CE Mark), Australian and FDA market approvals. Ms. Shaw understands the unique needs of innovative, technology-driven businesses and focuses on developing quality and regulatory strategies that are flexible enough to allow the creative innovations to thrive, while still focusing on the critical medical device regulatory priorities of safety and efficacy.
Board of Directors
Chairman of the Board & Co-founder
Managing Partner, Georgian Partners
Corporate Senior VP Zoll Medical
Managing Director, Broadview Ventures
Managing Partner, CTI Life Sciences Fund
President, Crimson Capital
Entrepreneur, Asia Pacific
CEO, CellAegis Devices Inc.